📊 HIT Key Takeaways
Is HIT a Good Investment? Thesis Analysis
Health In Tech faces significant headwinds with revenue declining 11.3% year-over-year in its insurance services business. While the company maintains a fortress balance sheet with no debt and strong liquidity, thin operating margins (5%) and weak return on equity (7.5%) indicate structural profitability challenges and poor capital efficiency. The marginal improvement in net income appears driven by cost-cutting rather than business expansion, suggesting the company is contracting rather than growing.
Why Buy HIT? Key Strengths
- Pristine balance sheet with zero debt and substantial cash position ($7.7M or 33% of total assets)
- Exceptional liquidity with 3.13x current ratio providing significant financial flexibility
- Healthy gross margin of 62.8% demonstrates strong pricing power in insurance services sector
- Positive free cash flow generation ($3.1M) despite revenue contraction
HIT Investment Risks to Consider
- Year-over-year revenue decline of 11.3% indicates core business contraction and potential market share loss
- Razor-thin operating margin (5.0%) and net margin (3.8%) provide minimal buffer against cost inflation or disruptions
- Weak return on equity (7.5%) and return on assets (5.5%) signal poor capital allocation and operational efficiency
- Zero insider buying activity in past 90 days suggests lack of management confidence in business prospects
Key Metrics to Watch
- Revenue trend - monitor whether 11.3% YoY decline continues, stabilizes, or reverses
- Operating margin sustainability - critical if revenue continues declining without proportional cost reductions
- Cash position and burn rate - ensure balance sheet strength is not consumed by operating losses
HIT Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.13x current ratio provides a solid financial cushion.
HIT Profitability Ratios
HIT vs Finance Sector
How Health In Tech, Inc. compares to Finance sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HIT Overvalued or Undervalued?
Based on fundamental analysis, Health In Tech, Inc. has mixed fundamental signals relative to the Finance sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HIT Balance Sheet & Liquidity
HIT 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Health In Tech, Inc.'s revenue has grown significantly by 92% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.01 reflects profitable operations.
HIT Growth Metrics (YoY)
HIT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.5M | $100.5K | $0.01 |
| Q2 2025 | $4.9M | $100.5K | $0.01 |
| Q1 2025 | $5.2M | $100.5K | $0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HIT Capital Allocation
HIT SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Health In Tech, Inc. (CIK: 0002019505)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HIT
What is the AI rating for HIT?
Health In Tech, Inc. (HIT) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are HIT's key strengths?
Claude: Pristine balance sheet with zero debt and substantial cash position ($7.7M or 33% of total assets). Exceptional liquidity with 3.13x current ratio providing significant financial flexibility.
What are the risks of investing in HIT?
Claude: Year-over-year revenue decline of 11.3% indicates core business contraction and potential market share loss. Razor-thin operating margin (5.0%) and net margin (3.8%) provide minimal buffer against cost inflation or disruptions.
What is HIT's revenue and growth?
Health In Tech, Inc. reported revenue of $33.3M.
Does HIT pay dividends?
Health In Tech, Inc. does not currently pay dividends.
Where can I find HIT SEC filings?
Official SEC filings for Health In Tech, Inc. (CIK: 0002019505) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HIT's EPS?
Health In Tech, Inc. has a diluted EPS of $0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HIT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Health In Tech, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HIT stock overvalued or undervalued?
Valuation metrics for HIT: ROE of 7.5% (sector avg: 12%), net margin of 3.8% (sector avg: 25%). Compare these metrics with sector averages to assess valuation.
Should I buy HIT stock in 2026?
Our dual AI analysis gives Health In Tech, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HIT's free cash flow?
Health In Tech, Inc.'s operating cash flow is $3.1M, with capital expenditures of N/A. FCF margin is 9.4%.
How does HIT compare to other Finance stocks?
Vs Finance sector averages: Net margin 3.8% (avg: 25%), ROE 7.5% (avg: 12%), current ratio 3.13 (avg: 1.2).